CNMD Conmed (CNMD) Insider Trading, Ownership & Congress Trades
Medical Devices · Electromedical & electrotherapeutic apparatus · CIK 0000816956
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
129
13F, latest reported quarter
Conversions, 180 days
6
Codes C/M, not in net · $0 priced
Conmed insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CONMED Corp in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on Feb 11, 2025.
- 1 other insider sold within 30 days.
- 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Information Officer Glaze Richard sold about $10.6K of CNMD on Nov 21, 2025; 1 other insider sold within 30 days and 129 funds added in the latest 13F quarter.Context
- 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Aug 7, 2025.
- The trade is 190.6% of the 1,836 shares held after it.
- 1 other insider sold within 30 days.
- 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President & CFO Garner Todd W sold about $150.5K of CNMD on Nov 6, 2025; 1 other insider sold within 30 days and 129 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 5, 2025.
- The trade is 7.0% of the 15,756 shares held after it.
- No other insider sold within 30 days.
- 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Farkas Charles sold about $59.1K of CNMD on Sep 12, 2025; 129 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 sale), the last on May 5, 2025.
- The trade is 6.0% of the 14,859 shares held after it.
- No other insider sold within 30 days.
- 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Farkas Charles sold about $48.0K of CNMD on Sep 12, 2025; 129 funds added in the latest 13F quarter.Context
- 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Aug 16, 2023.
- No other insider sold within 30 days.
- 129 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Executive Vice President & CFO Garner Todd W sold about $31.4K of CNMD on Aug 7, 2025; 129 funds added in the latest 13F quarter.118 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
129 funds bought in last quarter
more than 70% of Medical Devices
Revenue
+5.2% year over year
below 65% of Medical Devices
Margin
3.4% net margin
more than 71% of Medical Devices
Buybacks
$43.2M repurchased, FY to 2026-06-30
below 51% of Medical Devices
Short interest
6.6% of the float short (float per yahoo 2026-10-26) · 5.2 days to cover · settled 2026-09-30
more than 74% of Medical Devices
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CNMD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-1.2%12M
Insider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CNMD: institutional holders (13F)
13F holdings, latest reported quarter
4,820,739 sh
$157.8M
2,505,295 sh
$82.0M
2,188,761 sh
$71.6M
1,579,917 sh
$51.7M
1,417,468 sh
$46.4M
Congress trades in CNMD
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
CNMD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CNMD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Paradigm Micro-Cap Fund
$3.3M position · as of 2026-06-30
1.8%
Invenomic Fund
$13.8M position · as of 2026-07-31
1.6%
ROBO Global Healthcare Technology and Innovation ETF
$1.1M position · as of 2026-07-31
1.6%
State Street(R) SPDR(R) S&P(R) Health Care Equipment ETF
$2.2M position · as of 2026-06-30
1.5%
Small Cap Equity Portfolio
$13.3M position · as of 2026-07-31
1.3%
First Trust Small Cap Value AlphaDEX Fund
$1.7M position · as of 2026-07-31
0.9%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
2 registered trials, 2 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
2
Not applicable
2 active
What changed recently
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
2026-10-27 · Completion moved 2026-12 → 2027-05
Not applicable
BioBrace® Implant for Arthroscopic Repair of Full Thickness Rotator Cuff Tears
2026-10-27 · Recruiting → Active Not Recruiting
Not applicable
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return · Patrick J. Beyer
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$7.6M
$2.5M
$2.1M
-62%
+27%
2024
$7.4M
-$4.8M
$2.8M
-36%
+38%
2023
$7.8M
$13.3M
$2.5M
+1%
+24%
2022
$7.8M
-$8.3M
$3.1M
-19%
+14%
2021
$9.4M
$23.2M
$2.3M
+29%
+40%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 129 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CNMD financials
Revenue growth
+5.2%
XBRL, annual
Net margin
3.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Revenue, TTM CNMD
| FY Dec 2025 | $1.4B |
| FY Dec 2024 | $1.3B |
| FY Dec 2023 | $1.2B |
| FY Dec 2022 | $1.0B |
| FY Dec 2021 | $1.0B |
| Jun 2026 | $343.5M |
| Dec 2025 | $373.2M |
| Sep 2025 | $337.9M |
| Jun 2025 | $342.3M |
| Mar 2025 | $321.3M |
| Dec 2024 | $345.9M |
| Sep 2024 | $316.7M |
| Jun 2024 | $332.1M |
At each fiscal year end
Single quarter
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Net margin, TTM CNMD
| FY Dec 2025 | +3.4% |
| FY Dec 2024 | +10.1% |
| FY Dec 2023 | +5.2% |
| FY Dec 2022 | -7.7% |
| FY Dec 2021 | +6.2% |
| Jun 2026 | +6.7% |
| Dec 2025 | +4.5% |
| Sep 2025 | +0.8% |
| Jun 2025 | +6.3% |
| Mar 2025 | +1.9% |
| Dec 2024 | +9.8% |
| Sep 2024 | +15.5% |
| Jun 2024 | +9.0% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$150.9M
operating cash flow minus capex, 2025-01-01 to 2025-12-31
Free cash flow, TTM CNMD
| FY Dec 2025 | $150.9M |
| FY Dec 2024 | $153.9M |
| FY Dec 2023 | $106.3M |
| FY Dec 2022 | $11.6M |
| FY Dec 2021 | $96.9M |
| Jun 2026 | n/a |
| Dec 2025 | $41.2M |
| Sep 2025 | $48.5M |
| Jun 2025 | $23.4M |
| Mar 2025 | $37.8M |
| Dec 2024 | $39.3M |
| Sep 2024 | $47.8M |
| Jun 2024 | $39.7M |
At each fiscal year end
Single quarter
Debt to equity
0.64x
long-term 2026-06-30 plus current 2019-09-30; equity 2026-06-30
Debt to equity CNMD
| FY Dec 2025 | 0.82x |
| FY Dec 2024 | 0.95x |
| FY Dec 2023 | 1.18x |
| FY Dec 2022 | 1.34x |
| FY Dec 2021 | 0.87x |
| Jun 2026 | 0.64x |
| Dec 2025 | 0.82x |
| Sep 2025 | 0.86x |
| Jun 2025 | 0.89x |
| Mar 2025 | 0.93x |
| Dec 2024 | 0.95x |
| Sep 2024 | 1.02x |
| Jun 2024 | 1.11x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.25x
TTM operating cash flow over long-term 2026-06-30 plus current 2019-09-30
Cash flow to debt CNMD
| FY Dec 2025 | 0.20x |
| FY Dec 2024 | 0.18x |
| FY Dec 2023 | 0.13x |
| FY Dec 2022 | 0.03x |
| FY Dec 2021 | 0.16x |
| Jun 2026 | 0.25x |
| Dec 2025 | 0.20x |
| Sep 2025 | 0.19x |
| Jun 2025 | 0.18x |
| Mar 2025 | 0.20x |
| Dec 2024 | 0.18x |
| Sep 2024 | 0.19x |
| Jun 2024 | 0.18x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
fewer than four consecutive quarters of net income
Return on equity CNMD
| FY Dec 2025 | +4.7% |
| FY Dec 2024 | +14.7% |
| FY Dec 2023 | +8.2% |
| FY Dec 2022 | -10.5% |
| FY Dec 2021 | +8.4% |
| Jun 2026 | n/a |
| Dec 2025 | +4.7% |
| Sep 2025 | +6.6% |
| Jun 2025 | +11.7% |
| Mar 2025 | +13.0% |
| Dec 2024 | +14.7% |
| Sep 2024 | +15.2% |
| Jun 2024 | +11.9% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
n/a
fewer than four consecutive quarters of net income
Return on assets CNMD
| FY Dec 2025 | +2.0% |
| FY Dec 2024 | +5.7% |
| FY Dec 2023 | +2.8% |
| FY Dec 2022 | -4.0% |
| FY Dec 2021 | +3.6% |
| Jun 2026 | n/a |
| Dec 2025 | +2.0% |
| Sep 2025 | +2.8% |
| Jun 2025 | +4.8% |
| Mar 2025 | +5.2% |
| Dec 2024 | +5.7% |
| Sep 2024 | +5.7% |
| Jun 2024 | +4.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
fewer than four consecutive quarters of operating income
Return on invested capital CNMD
| FY Dec 2025 | +3.7% |
| FY Dec 2024 | +9.1% |
| FY Dec 2023 | +5.5% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +6.7% |
| Jun 2026 | n/a |
| Dec 2025 | +3.7% |
| Sep 2025 | +4.9% |
| Jun 2025 | +7.6% |
| Mar 2025 | +8.2% |
| Dec 2024 | +9.1% |
| Sep 2024 | +9.1% |
| Jun 2024 | +7.2% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
n/a
fewer than four consecutive quarters of operating income
Return on capital employed CNMD
| FY Dec 2025 | +5.1% |
| FY Dec 2024 | +10.0% |
| FY Dec 2023 | +6.0% |
| FY Dec 2022 | +3.9% |
| FY Dec 2021 | +7.0% |
| Jun 2026 | n/a |
| Dec 2025 | +5.1% |
| Sep 2025 | +5.9% |
| Jun 2025 | +8.5% |
| Mar 2025 | +9.0% |
| Dec 2024 | +10.0% |
| Sep 2024 | +9.9% |
| Jun 2024 | +8.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
fewer than four consecutive quarters of diluted EPS
P/E, trailing CNMD
| FY Dec 2025 | 26.89x |
| FY Dec 2024 | 16.14x |
| FY Dec 2023 | 53.68x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 73.07x |
| Jun 2026 | n/a |
| Dec 2025 | 26.89x |
| Sep 2025 | 22.94x |
| Jun 2025 | 14.75x |
| Mar 2025 | 15.89x |
| Dec 2024 | 16.14x |
| Sep 2024 | 17.08x |
| Jun 2024 | 22.08x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$2.1B
market value at close 2026-10-26 on 2026-07-27 shares, plus long-term 2026-06-30 plus current 2019-09-30, minus cash 2019-12-31
Enterprise value CNMD
| FY Dec 2025 | $2.1B |
| FY Dec 2024 | $3.0B |
| FY Dec 2023 | $4.3B |
| FY Dec 2022 | $3.7B |
| FY Dec 2021 | $4.8B |
| Jun 2026 | $1.7B |
| Dec 2025 | $2.1B |
| Sep 2025 | $2.3B |
| Jun 2025 | $2.5B |
| Mar 2025 | $2.7B |
| Dec 2024 | $3.0B |
| Sep 2024 | $3.1B |
| Jun 2024 | $3.1B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+10.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield CNMD
| FY Dec 2025 | +12.0% |
| FY Dec 2024 | +7.3% |
| FY Dec 2023 | +3.2% |
| FY Dec 2022 | +0.4% |
| FY Dec 2021 | +2.3% |
| Jun 2026 | +15.0% |
| Dec 2025 | +12.0% |
| Sep 2025 | +10.2% |
| Jun 2025 | +9.2% |
| Mar 2025 | +8.8% |
| Dec 2024 | +7.3% |
| Sep 2024 | +7.5% |
| Jun 2024 | +7.5% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
fewer than four consecutive quarters of diluted EPS
PEG, trailing CNMD
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.15x |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 0.12x |
| Jun 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | 1.19x |
| Mar 2025 | 0.35x |
| Dec 2024 | 0.15x |
| Sep 2024 | 0.14x |
| Jun 2024 | 2.45x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $1.4B | $1.3B | $1.2B | $1.0B |
| Gross profit | $750.5M | $733.0M | $676.2M | $571.2M |
| Operating income | $102.6M | $200.3M | $120.6M | $70.1M |
| Net income | $47.1M | $132.4M | $64.5M | -$80.6M |
| EPS (diluted) | 1.51 | 4.25 | 2.04 | -2.68 |
| Operating cash flow | $170.7M | $167.0M | $125.3M | $33.4M |
| Long-term debt | $834.2M | $905.1M | $973.1M | $985.1M |
| Dividends paid | $24.7M | $24.7M | $24.5M | $24.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
CNMD Stock Sonar score 4/7 axes
Find similar shapesCompareCNMD ranks highest on institutional and government (70th percentile) and financial health (53rd), and lowest on risk and compliance (20th), among Medical Devices peers.
4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
